Science and animal rights can move in the same direction.
On April 10, 2025, the Food and Drug Administration (FDA), the U.S. agency that regulates drugs and other health products, announced a plan to reduce, refine, and, where possible, replace certain animal tests in drug development. The starting point is monoclonal antibodies, with the aim of gradually extending the approach to other categories of medicines.
This is not a blanket ban on animal testing, nor has the replacement of animal studies already been achieved. But it is a substantial step: a stated commitment to evaluating drug safety using data and models that are more directly relevant to humans.
Read more